Association of sodium‐glucose cotransporter 2 inhibitors with risk of incident dementia and all‐cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks

医学 危险系数 痴呆 内科学 队列 回顾性队列研究 2型糖尿病 二甲双胍 队列研究 倾向得分匹配 相对风险 糖尿病 置信区间 内分泌学 胰岛素 疾病
作者
Yen‐Wei Pai,I‐Chieh Chen,Jun‐Fu Lin,Xiaohong Chen,Hsin‐Hua Chen,Ming‐Hong Chang,Jin‐An Huang,Ching‐Heng Lin
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
被引量:1
标识
DOI:10.1111/dom.15918
摘要

Abstract Background Limited evidence exists to support any specific medication over others to prevent dementia in older patients with type 2 diabetes (T2D). We investigated whether treatment with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors is associated with a lower risk of incident dementia and all‐cause mortality, relative to dipeptidyl peptidase‐4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA). Methods In this retrospective, active‐comparator cohort study, we used data from the TriNetX electronic health records network. Our primary cohort comprised patients with T2D aged ≥50 years, registered between January 2012 and December 2022. Patients with a history of dementia were excluded. We used Kaplan–Meier survival analysis to estimate the incidence of dementia and all‐cause mortality in our cohort after they had used glucose‐lowering drugs for at least 12 months. Propensity score matching was performed to balance the SGLT‐2 inhibitor, DPP‐4 inhibitor and GLP‐1 RA cohorts. Subgroup analyses for sex and age were also conducted. Results Our first cohort comprised 193 948 patients treated with metformin and SGLT‐2 inhibitors and an equal number of patients treated with metformin and DPP‐4 inhibitors. In this cohort, the risk of dementia and all‐cause mortality was lower in patients treated with SGLT‐2 inhibitors than in those treated with DPP‐4 inhibitors (hazard ratio [HR]: 0.62, 95% confidence interval [CI]: 0.59–0.65, for dementia; HR: 0.54, 95% CI: 0.52–0.56, for all‐cause mortality). Our second cohort comprised 165 566 patients treated with metformin and SGLT‐2 inhibitors and an equal number of patients treated with metformin and GLP‐1 RAs. In this cohort, the risk of dementia and all‐cause mortality was lower in those treated with SGLT‐2 inhibitors than in those treated with GLP‐1 RAs (HR: 0.92, 95% CI: 0.87–0.98, for dementia; HR: 0.88, 95% CI: 0.85–0.91, for all‐cause mortality). Conclusions The use of SGLT‐2 inhibitor was associated with a lower risk of incident dementia and all‐cause mortality in older adults with T2D compared to DPP‐4 inhibitor and GLP‐1 RA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
酸奶烤着吃完成签到,获得积分10
2秒前
3秒前
3秒前
3秒前
刘亚茹发布了新的文献求助10
3秒前
留胡子的霆完成签到,获得积分10
4秒前
可爱的函函应助魏少爷采纳,获得10
7秒前
端庄涟妖发布了新的文献求助10
7秒前
坦率的寻双完成签到,获得积分10
7秒前
stitchkk应助cllg采纳,获得10
9秒前
9秒前
黄百川完成签到 ,获得积分10
11秒前
13秒前
14秒前
Fengh发布了新的文献求助10
14秒前
炎魔之王拉格纳罗斯完成签到,获得积分10
15秒前
机智的白昼完成签到,获得积分20
17秒前
17秒前
18秒前
孙成成发布了新的文献求助10
18秒前
Rondab应助xx采纳,获得10
18秒前
量子星尘发布了新的文献求助10
19秒前
欣欣子发布了新的文献求助10
20秒前
七七发布了新的文献求助10
22秒前
予安发布了新的文献求助10
23秒前
28秒前
pluto应助光亮笑柳采纳,获得10
30秒前
小小吴完成签到,获得积分10
30秒前
无问西东发布了新的文献求助20
32秒前
dkyt发布了新的文献求助10
32秒前
大模型应助lgw采纳,获得10
32秒前
七七完成签到,获得积分10
34秒前
Hello应助信仰阳光快乐采纳,获得10
35秒前
37秒前
略略完成签到,获得积分10
40秒前
向风完成签到,获得积分10
41秒前
饱满南松发布了新的文献求助10
42秒前
聪明的云完成签到 ,获得积分10
42秒前
43秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975543
求助须知:如何正确求助?哪些是违规求助? 3519971
关于积分的说明 11200248
捐赠科研通 3256311
什么是DOI,文献DOI怎么找? 1798213
邀请新用户注册赠送积分活动 877446
科研通“疑难数据库(出版商)”最低求助积分说明 806338